Andrew Cox, Pharm.D., MBA

Restricting the study to treatment-naive patients allowed researchers to isolate changes due to natural disease.

Post-hoc analysis shows potential of biomarkers for identifying pancreatic patients who respond to treatment.

MHE has a conversation with Renuka Iyer, M.D., who became CMO of NCCN in early December. Iyer is aiming to enhance evidence-based cancer care and expand guidelines for rare cancers and diverse populations.

The medical director of The US Oncology Network discusses adherence to clinical pathways, CAR-T therapy and concerns about the consequences of drug price negotiation under the Inflation Reduction Act.

A Brazilian study shows a correlation between circulating tumor cell and overall survival in a trial assessing a treatment of gastric cancer.

The data further identify ctDNA as a dependable biomarker for assessing response to bispecific antibody treatment

By 2020, only 10.8% of adults aged 50 and older had completed both doses of the recombinant zoster vaccine,with 14.1% receiving at least one.

An analysis of patients with stage III colon patients found celecoxib improves survival only in those who are positive for circulating tumor DNA.

Teva's new olanzapine LAI aims to enhance schizophrenia treatment by improving adherence and reducing relapse risks, pending FDA approval.

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for improved dietary quality for prevention.

Larger and longer studies are needed. But the positive results for semaglutide stand in contrast to those for metformin and topiramate.

By identifying the isoforms of the prostate-specific antigen (PSA), the new test may distinguish between prostate cancer and other causes of elevated PSA levels.

GLP-1 receptor agonists significantly lower five-year mortality in highly obese colon cancer patients, highlighting potential benefits beyond weight loss and inflammation reduction.

High levels of integrin beta-6 (IB6) in metastatic non-small cell lung cancer suggest that it could be a target for treatment.

New research highlights DR-70 as a promising noninvasive biomarker for diagnosing and staging bladder cancer, potentially improving early detection strategies.

A study reveals circulating tumor cells (CTCs) as potential biomarkers for predicting aggressive DCIS, aiming to reduce overtreatment and improve patient outcomes.

Research summarized in posters at AMCP Nexus shows that long-acting injectables can help with the problem of adherence.

Consistent moderate physical activity significantly reduces the risk of digestive system cancers, highlighting the importance of long-term exercise for prevention.

Next-generation sequencing (NGS) holds great promise for identifying 'tumor-agnostic' therapies, but evidence does not support its routine use in clinical care and diagnosis of sarcoma, a consensus statement concludes.

New findings from the MATTERHORN trial reveal durvalumab combined with FLOT chemotherapy significantly improves survival in early-stage gastric cancer patients.

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires cautious adoption and patient-centered decision-making in clinical practice.

CT-155 is a smartphone app that integrates psychosocial interventions delivered using an adaptive goal-setting technique. A phase 3 trial has demonstrated that it can reduce the negative symptoms of schizophrenia.

New research clarifies the definition of "cure" in stage II and III colon cancer, highlighting a six-year milestone for patient reassurance and care efficiency.